HCA Healthcare (HCA) is up 4.7% today. Here is some analysis on what might have caused this price movement. ([investor.hcahealthcare.com](https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Second-Quarter-2026-Results/default.aspx?utm_source=openai))

Analysis: The move appears tied to HCA’s second-quarter 2026 results and follow-up investor messaging, which highlighted revenue growth, higher admissions, and continued pricing strength. This could also reflect investors responding positively to large share repurchases and a maintained dividend after a period of concern around payer mix and uninsured volumes. ([investor.hcahealthcare.com](https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Second-Quarter-2026-Results/default.aspx?utm_source=openai))

Details:

  • Second-quarter revenue rose to $20.23 billion, helped by a 2.6% increase in equivalent admissions and a 6.0% increase in revenue per equivalent admission. ([investor.hcahealthcare.com](https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Second-Quarter-2026-Results/default.aspx?utm_source=openai))
  • Net income reached $1.699 billion, or $7.62 per diluted share, up from $1.653 billion, or $6.83 per diluted share, a year earlier. ([investor.hcahealthcare.com](https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Second-Quarter-2026-Results/default.aspx?utm_source=openai))
  • HCA repurchased 4.752 million shares for about $2.064 billion during the quarter, and the board declared a quarterly cash dividend of $0.78 per share. ([investor.hcahealthcare.com](https://investor.hcahealthcare.com/news/news-details/2026/HCA-Healthcare-Reports-Second-Quarter-2026-Results/default.aspx?utm_source=openai))
  • Even with those positives, investors had recently been weighing reimbursement and coverage pressure tied to more uninsured patients, so part of today’s gain may simply be a rebound as the market reassesses that risk against still-strong operating trends. ([healthcaredive.com](https://www.healthcaredive.com/news/hca-healthcare-q2-2026-aca-patients-uninsured-surgeries/826113/?utm_source=openai))
  • Sources:

    HCA Healthcare Investor Relations, SEC, Healthcare Dive

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $HCA Hedge Fund Activity

    We have seen 563 institutional investors add shares of $HCA stock to their portfolio, and 838 decrease their positions in their most recent quarter.

    See also  fuboTV Stock (FUBO) Opinions on Analyst Recommendation and Channel Additions

    Here are some of the largest recent moves:

    To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $HCA Congressional Stock Trading

    Members of Congress have traded $HCA stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

    Here’s a breakdown of recent trading of $HCA stock by members of Congress over the last 6 months:

    To track congressional stock trading, check out Quiver Quantitative’s congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

    $HCA Price Targets

    Multiple analysts have issued price targets for $HCA recently. We have seen 12 analysts offer price targets for $HCA in the last 6 months, with a median target of $522.5.

    See also  Jensen Huang Doubled Nvidia's Own Sales Forecast to $1 Trillion Through 2027. Here's What That Guidance Means for the Stock's Valuation.

    Here are some recent targets:

    • Andrew Mok from Barclays set a target price of $427.0 on 07/08/2026
    • Sarah James from Cantor Fitzgerald set a target price of $525.0 on 07/07/2026
    • Ryan Langston from TD Cowen set a target price of $431.0 on 06/22/2026
    • Lance Wilkes from Bernstein set a target price of $413.0 on 06/04/2026
    • David Macdonald from Truist Securities set a target price of $535.0 on 04/27/2026
    • Matthew Gillmor from Keybanc set a target price of $510.0 on 04/27/2026
    • Michael Wiederhorn from Oppenheimer set a target price of $520.0 on 04/27/2026

    This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.


    Source link